Johnson & Johnson (NYSE:JNJ) Stock Position Raised by Kestra Investment Management LLC

Kestra Investment Management LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 16.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,422 shares of the company's stock after acquiring an additional 3,499 shares during the quarter. Kestra Investment Management LLC's holdings in Johnson & Johnson were worth $3,532,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. IFS Advisors LLC increased its holdings in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after buying an additional 100 shares during the last quarter. Highline Wealth Partners LLC purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at $31,000. Bay Harbor Wealth Management LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $32,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of Johnson & Johnson in the 3rd quarter valued at about $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC increased its position in Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock worth $40,000 after buying an additional 91 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mark A. Weinberger bought 1,000 shares of the business's stock in a transaction on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Up 1.7 %

Shares of JNJ stock traded up $2.67 during mid-day trading on Friday, reaching $162.35. 12,540,171 shares of the company were exchanged, compared to its average volume of 9,073,381. The company has a market capitalization of $390.87 billion, a P/E ratio of 24.41, a P/E/G ratio of 2.53 and a beta of 0.52. The business's 50 day simple moving average is $148.61 and its 200 day simple moving average is $155.89. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the previous year, the firm earned $2.29 EPS. The company's revenue was up 5.3% on a year-over-year basis. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.06%. Johnson & Johnson's dividend payout ratio (DPR) is 74.59%.

Analyst Upgrades and Downgrades

JNJ has been the subject of several research analyst reports. Barclays increased their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a report on Tuesday, January 28th. Royal Bank of Canada reissued an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday. Argus raised shares of Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Leerink Partners lowered their target price on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a research note on Thursday, January 23rd. Finally, Raymond James dropped their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a research note on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $170.67.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.